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Non β-cellsThe tryptophan/kynurenine pathway (TKP) is the main route of tryptophan degradation and generates several
neuroactive and immunomodulatory metabolites. Experimental and clinical data have clearly established that
besides fat, muscle and liver, pancreatic islet tissue itself is a site of inﬂammation during obesity and type 2
diabetes. Therefore it is conceivable that pancreatic islet exposure to increased levels of cytokines may induce
upregulation of islet kynurenine metabolism in a way resembling that seen in the brain in many neurodegener-
ative disorders. Using normal rat islets and the INS-1 β-cell line, we have demonstrated for the ﬁrst time that: 1/
only some TKP genes are constitutively expressed, both inβ-cells aswell as nonβ-cells; 2/ the regulatory enzyme
indoleamine 2,3-dioxygenase (IDO1) is not constitutively expressed; 3/ IDO1 and kynurenine 3-monoxygenase
(KMO) expression are potently activated by proinﬂammatory cytokines (IFN-γ, IL-1β) and glucolipotoxicity
respectively, rather inβ-cells than in nonβ-cells; 4/ Islet kynurenine/kynurenic acid production ratio is enhanced
following IFN-γ and glucolipotoxicity; 5/ acute exposure to KYN potentiates glucose-induced insulin secretion by
normal islets; and 6/ oxidative stress or glucocorticoid modulates TKP genes only marginally. Pancreatic islets
may represent a new target tissue for inﬂammation and glucolipotoxicity to activate the TKP. Since inﬂammation
is now recognized as a crucialmechanism in thedevelopment of themetabolic syndromeandmore speciﬁcally at
the islet level, it is needed to evaluate the potential induction of the TKP in the endocrine pancreas during obesity
and/or diabetes and its relationship to the islet cell functional alterations.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The tryptophan/kynurenine pathway (TKP) is the main route of
tryptophan degradation in the human body and generates several
neuroactive and immunomodulatory metabolites [1,2]. The ﬁrst step
in the TKP (Fig. 1) is characterized by the oxidation of tryptophan to, insulin secreting β-cell line
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a).N-formylkynurenine by the enzymes tryptophan 2,3-dioxygenase
(TDO2) and indoleamine 2,3-dioxygenase (IDO1) [3–5]. TDO2 has
been localized primarily in the liver, but has also been found in the
brain, and is induced in the liver by tryptophan and corticosteroids [3,
4]. IDO1, on the other hand, has been identiﬁed in several extrahepatic
tissues, including the brain, and is up-regulated by cytokines and
proinﬂammatory agents such as lipopolysaccharides [6], amyloid
peptides [7], HIV proteins [8] and tumor cells [9]. However, its most
potent stimulus is interferon-gamma (IFN-γ) [10]. The catabolite of
tryptophan, N-formylkynurenine, is then hydrolyzed to form the ﬁrst
stable metabolite, kynurenine (KYN), by the action of kynurenine
formamidase [11]. KYN can then be transformed by selected enzymatic
activity to kynurenic acid (KYNA) and picolinic acid (PIC) side branches
before complete catabolism to NAD+. Importantly, not all tryptophan
catabolism by the kynurenine pathway is directed towards the
formation of intracellular NAD+ [12]. A signiﬁcant proportion of the
tryptophan catabolites, KYN, KYNA, quinolinic acid (QUIN) and PIC
leak out of the cell to exert as yet incompletely characterized biological
activity. QUIN has been identiﬁed as a selective agonist, and KYNA as a
selective antagonist, at the ubiquitous N-methyl-d-aspartate (NMDA)
receptor in the central nervous system [13,14]. NMDA receptor
activity has been implicated in both normal central nervous system
Fig. 1.Thekynurenine pathway for the oxidativemetabolismof tryptophan inmammalian
cells.
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likely that both QUIN and KYNA are actively involved in brain function
and dysfunction [2,15–17]. Indeed, altered levels of TKP metabolites
have been observed in multiple neuropsychiatric and neurodegenera-
tive disorders [18–21] as well as in patients with affective disorders
[22–26].
Importantly, several studies have shown that infections activate the
TKP, which thereby appear to serve both as a direct defensemechanism
and as a means of modulating the immune response [1,27,28].
Signiﬁcant changes in TKP metabolism have also been reported in
the brain, liver and kidney of rats with advancing age [29]. Although
the cause or causes of these effects are still unknown, it is postulated
that these changes are probably associated with the age-dependent
increase in cellular and tissue damage that is mediated by increasing
levels of free radicals and reactive oxygen species.
In neuronal cells, besides robust IDO1 induction by theproinﬂamma-
tory cytokine interferon IFN-γ [30,31], it is not clear if pro-inﬂammatory
cytokines affect expression of genes encoding other enzymes of the TKP.
Concerning pancreatic β-cells, it is known that they share with
neuronal cells a large number of similarities. Different enzymes impli-
cated in the synthesis of γ-aminobutyric acid or catecholamines, of
speciﬁc cell-surface receptors for growth factors and amino acids, of
speciﬁc intermediate ﬁlaments such as neuroﬁlament, and of hormones
such as thyrotropin-releasing hormone have been shown to be
expressed in both neuronal and β-cells at different stages of their devel-
opment [32]. Moreover, β-cells also resemble neurons by being electri-
cally excitable and by responding to hormonal stimuli and glucose by
depolarization and exocytosis in a process similar to neurotransmitter
release from synaptic vesicles [32]. It has beenproposed that similarities
between β and neuronal cells are related to the expression in both cell
types of identical transcriptional activators such as the transcriptional
activator NeuroD/Β2 [32], and to the lack of expression in both cell
types of speciﬁc transcriptional repressors such as NRSF/REST [33].
Experimental and clinical data have clearly established that besides
fat,muscle and liver, pancreatic islet tissue itself is a site of inﬂammation
during obesity and type 2 diabetes [34]. Therefore it is conceivable that
in parallel to the high free fatty acids and glucose levels, pancreatic islet
exposure to increased levels of cytokines may induce dysregulation of
islet TKP in a way resembling that seen in the brain in many neurode-
generative disorders. Recently, IDO1 expression was detected for the
ﬁrst time in human adipose tissue and found increased in adipose and
liver tissues from obese patients in conjunction with obesity-induced
low-grade inﬂammation [35].While one study has reported a remarkable induction of IDO1
transcripts in human islets in response to cytokine-mediated inﬂamma-
tion [36], expression or functionality of genes encoding downstream
enzymes in the TKPhave never been investigated extensively in pancre-
atic endocrine cells. Since it is recognized that the TKP is cell-type
dependent and can be controlled locally or systematically by different
stimuli [37], it is of major importance to study the TKP in pancreatic
islets, both in basal normal situation and in response to factors which
might contribute to impair pancreatic islet cells such as exposure to
cytokines, oxidative stress, high free fatty acids and high glucose levels.
In the present study, we investigated if transcripts encoding enzymes in
the TKP can be detected in normal rodent islet cells, and if their relative
abundances are modulated by IFN-γ, IL-1β, glucolipotoxicity, ROS
exposure or glucocorticoids.
2. Materials and methods
2.1. Materials
Cell culture medium was from Lonza, Montigny-Le-Bretonneux,
France. Fetal bovine serumwas from Biowest, Nuaillé, France. Cytokines
were from Millipore, Fontenay sous Bois, France. Fatty-acid free BSA
powders were from Roche Applied Science, Meylan, France. Apo-
ONE® Homogenous Caspase-3/7 Assay kit was from Promega,
Charbonnieres, France. RNA isolation kit was from Qiagen, Courtaboeuf,
France. Reverse transcriptase kit was from Invitrogene, Saint Aubin,
France. Real-time PCR kit was from Roche Applied Science, Meylan,
France. All western blot materials were from BioRad, Marnes-la-
Coquette, France. Rat insulin ELISA kit was from Alpco, Eurobio, Les
Ulis, France. All solvents were from VWR, Fontenay-sous-Bois, France
or Fisher Scientiﬁc, Illkirch, France, and all other chemicals used were
from Sigma-Aldrich, Saint-Quentin Fallavier, France.
2.2. Rat islet isolation
Isolated islets were obtained from 10 to 13 week old male Wistar
rats from our local colony bred in accordance with accepted standards
of animal care as established by the French National Centre for Scientiﬁc
Research. Pancreatic islets were isolated by collagenase digestion
and Ficoll gradient puriﬁcation. Islets were handpicked under a stereo-
microscope as previously described [38].
2.3. Rat islet and β-cell line culture conditions
Rat islets were cultured in 2 ml of RPMI 1640 containing 10 mM
glucose and supplemented with penicillin-streptomycin (500 U/ml),
2 mM L-glutamine, and 10% heat-inactivated fetal bovine serum. Islets
were maintained free ﬂoating at 37 °C in a humidiﬁed atmosphere of
95%O2–5%CO2 until initiation of experiments.
Rat insulinoma INS-1 cells (clone 368), kindly provided by Merck-
Serono, were grown in the same RPMI 1640 medium as described
above and further supplemented with 50 μM 2-mercaptoethanol. Cells
were plated for 48 h in 96-well plates (5 × 104 cells/well) for MTT
assay and caspase 3/7 activity, in 12-well plates (5 × 105 cells/well)
for insulin secretion.
Batches of 100 islets or 106 INS-1 cells (in 6-wells plates) were
incubated in the absence or presence of cytokines, namely 500 units/
ml interleukin IL-1β or 2500units/ml IFN-γ (). In oxidative stress exper-
iments, islets or INS-1 cells were pretreated with 50 μM H2O2 alone for
30 min and then washed twice with PBS before islets were cultured for
48 h in RPMI 1640 medium. In glucolipotoxicity experiments, islets or
INS-1 cells were cultured for 48 h with or without palmitate (0.4 mM)
in the presence of 10 mM (control) or 20 mM (G20) glucose. Palmitate
was administered to the islets or INS-1 cells as a conjugate with fatty-
acid free BSA. Brieﬂy, dried aliquots of palmitate in ethanol were
dissolved in PBS containing 13% (w/v) BSA to obtain a 10 mM stock
Table 1
Transcripts analyzed by real-time PCR, gene symbols and primer sequences.
Target transcript Gene Polarity Sequence (5′→ 3′)
IDO1 INDO Sense CAGTAGAGCATCAAGACCCGA
Anti-sense CCAACCAGACAAATATATGCGAAG
TDO TDO2 Sense CTGCTCTGCTTGTTCGATGAGAA
Anti-sense AGTGTGTCAATGTCCATAAGTGAGG
KMO KMO Sense GGAGGAAGGGATACTCACGATG
Anti-sense CCCGTTCTTAGGTGGAATTGTC
KAT1 CCBL1 Sense CAATGATGGCTGGAGGTTG
Anti-sense GTTGTTGGGTGTGTTGAGGA
KAT2 AADAT Sense ACATCATCTCCCTGGCTCCT
Anti-sense TGGTGCTTCCGTTCTCCAC
KAT3 CCBL2 Sense GATTCAAAAATGCCAAACGAA
Anti-sense CCAAGATTCACCACAGAAGGA
KAT4 GOT2 Sense TATGCCAAGAACATGGGCCT
Anti-sense GATCTTCAGCTGTGACTCCA
Kase KYNU Sense GGCTGTTTTGTTGGCTTTGACCTA
Anti-sense CCGAACCATCCCACTAACGC
QPRT QPRT Sense TGGACATGTAGCAGGCACGA
Anti-sense CAGGTCATAGCGGTGGCATT
ACMSD Sense CCAAAGGAATGGCCTGATCT
Anti-sense CTGAAGACCTTCCCGTCTTT
NAMPT Sense CAGAAGCCGAGTTCAACATC
Anti-sense TTTCACGGCATTCAAAGTAGG
TBP Sense Sense CGTGAATCTTGGCTGTAAACTTGA
Anti-sense GCTGCTAGTCTGGATTGTTCTTCA
Cyclophiline A Sense AACCCACCGTGTTCTTC
Anti-sense TGCCTTCTTTCACCTTCCC
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stock solution was diluted in RPMI 1640 medium supplemented with
10% FBS to obtain a 0.4 mM ﬁnal concentration at a ﬁxed concentration
of 0.5% BSA.
2.4. Rat islet cell preparation and ﬂuorescence-activated cell sorting of non
β- and β-cells
Rat islets were trypsinized with trypsin (0.05%, Gibco, St Aubin,
France) and digestion was stopped with cold Krebs–Ringer–bicarbon-
ate–Hepes (KRBH) buffer—0.5% BSA (fatty-acid free) with 5.5 mM
glucose. Cell suspensions were used for β-cell sorting. Using a
FACSAriaII (Becton Dickinson, Pont De Claix, France), β-cells were
distinguished from non β-cells and sorted based on their autoﬂuores-
cence (FAD content) and cell size as previously described [39,40],
resulting between our hands in a populationwith 94% (insulin-positive)
β-cells as a mean. Data were analyzed using FACS DIVA analysis
software (Becton Dickinson). Sorted β-cells and non β-cells were used
for total RNA extractions or immunolabeling.
2.5. Immunolabeling on pancreas sections, isolated islets and isolated islet
cells
Rat pancreas and isolated islets were ﬁxed in Bouin solution and
embedded in parafﬁn for section. Isolated islet cells were ﬁxed by 4%
paraformaldehyde and permeabilized with 0.1% Triton X-100. Antigen
retrieval was performed in a water bath for 15 min in a citrate buffer
(pH 4) at 100 °C. The sections were blocked for 1 h with 10% normal
goat serum in PBS. Multiple immunoﬂuorescence labeling was
performed with antibodies raised against IDO1 (1:50, Abcam), KMO
(1:150, Abcam,), insulin (1:300,MPBiomedicals, Illkirch, France), gluca-
gon (1:300, Boster, Interchim, Montluçon, France). Sections were then
incubated with a mix of Alexa488-conjugated anti-rabbit (1:300,
Invitrogen, St Aubin, France) and Alexa594-conjugated anti-mouse
(1:300, Interchim, Montluçon, France) or Rhodamine X Red conjugated
anti-Guinea pig (1:300, Vectorlabs, Eurobio, Les Ulis, France) secondary
antibodies. Confocal images were acquired by Zeiss LSM 710
microscopy.
2.6. Quantitative PCR
Total RNA was extracted from rat islets, puriﬁed rat β-cells, non β-
cells or INS-1 cells using the RNeasy mini kit. cDNA of each RNA sample
was synthesized with MMLV (Moloney murine leukemia virus) reverse
transcriptase using random hexamer primers. The primers used for PCR
were derived from rat sequences and designed using OLIGO6 (the
primer sets are described in Table 1). Real-time quantitative PCR ampli-
ﬁcation reactionswere carried out in a LightCycler 480 detection system
(Roche Applied Science) using the LightCycler SYBR Green 480 kit.
Approximately 10 ng cDNA was used as the template for each reaction.
All reactions were run in duplicate with no template control. The PCR
conditions were: 95 °C for 10 min, followed by 40 cycles at 95 °C for
10 s, 60 °C for 10 s and 72 °C for 10 s. mRNA transcript levels of four
housekeeping genes [encoding rpL19 (ribosomal protein L19), TBP
(TATA-box binding protein), cyclophilin A and 18S] were assayed.
Since similar results were obtained with the four housekeeping genes,
only cyclophilin A was retained for normalization of other transcripts.
2.7. Western blotting
Equal amounts of proteins were separated by SDS/PAGE (12% gels)
and then transblotted to PVDF membrane. The membranes were
blocked with 5% (w/v) nonfat dry milk in TBS containing 0.05% (v/v)
Tween 20. Blots were probed with a polyclonal anti-KMO antibody
(1:500, Abcam), stripped and re-probed with a monoclonal anti-β-
actin antibody (1:1000, Sigma-Aldrich). Immunoreactive bandswere visualized by enhanced chemiluminescence with appropriate
horseradish peroxidase-conjugated secondary antibody (Jackson
ImmunoResearch Laboratories, Interchim).
2.8. Quantiﬁcation of kynurenine and kynurenic acid
Levels of KYN and KYNA in islet culture media were determined
using a liquid chromatography-tandem mass spectrometry (LC-MS/
MS) method. In short, culture medium samples were precipitated
withmethanol for Trp and KYN, or perchloric acid for KYNA, respective-
ly. After centrifugation, the clear supernatant was injected into the LC-
MS/MS system. Chromatographic separation was achieved on an Atlan-
tis dC18 reverse phase column (C18, 3 μm, 20 × 4.6 mm (int. diam.))
and elution with (A) HCO2H 0.1% (for positive mode on MS/MS), for
1 min and from A to (B) CH3CN: A (40:60, v/v) in 2 min and for 2 min
in B on a Agilent 1200 system with a quaternary pump. MS/MS was
performed on an API 3200 LC-MS/MS spectrometer (Applied
Biosystems/MDS Sciex, Villebon s Yvette, France) operated with a
Turbo Ion Spray source in positive mode, looking for mass transition
(MRMmode). Calibration ranges were 1–10,000 ng/ml for Trp, and 1–
1000 ng/ml for KYN and KYNA, respectively.
2.9. Measurement of caspase 3/7 activity
Caspase 3/7 activity assays were performed using the Promega Apo-
ONE®Homogenous Caspase-3/7 Assay kit, as previously described [41].
Brieﬂy, lysis buffer containing the ﬂuorigenic Z-DEVD-R110
(benzyloxycarbonyl-Asp-Glu-Val-Asp-rhodamine 110) substrate was
added to each well and ﬂuorescence was measured every 6 min over a
120 min period using a FLUOstar plate reader (MTX Lab Systems,
Virginia, USA) set at 37 °C (ex:499 nm, and em:521 nm). Caspase 3/7
speciﬁc activity was expressed as the slope of the kinetic in arbitrary
units. Each experimental condition tested was performed in triplicate.
2.10. Measurement of glucose-stimulated insulin secretion
At the end of the culture period, INS-1 cells were pre-incubated in
KRBH (Krebs– Ringer/bicarbonate/Hepes) containing 0.2% fatty-acid-
free BSA and 0.5 mM glucose for 1 h. Insulin secretion was measured
Fig. 2. Relative levels of transcripts encoding TKP enzymes in normal rat islets and INS-1
cells. (A) Reverse transcriptase-PCR analysis of TKP key enzymes. cDNAswere synthesized
from fresh isolated rats islets. Ampliﬁcations of TDO2, IDO1, KMO, Kase, QPRT, ACMSD,
NAMPT, and KAT1–4 are shown in lanes 2–12. Expected size of each PCR product was
respectively: TDO2: 170 bp, IDO1: 152 bp, KMO: 190, KASE: 191 bp, QPRT: 100 bp,
ACMSD 110 bp, NAMPT: 110 bp, KAT1: 161 bp, KAT2: 87 bp, KAT3: 94 bp, and KAT4:
102 bp. PCR product is not detected if reverse transcriptase is omitted from the reaction
tube. However, IDO1 and ACMSD could be ampliﬁed in samples respectively obtained
from IFNγ-treated rat islets and liver tissue (not shown). Therefore the absence of band
in (A) experiments suggests that IDO1 and ACMSD expression levels in normal rat islets
were undetectable under basal condition. (B) Relative levels of transcripts encoding TKP
enzymes in normal rat islets (open bars) and INS-1 cells are shown (hatched bars).
(C) Fresh isolated rat islets were trypsinized and cell populations sorted by FACS. Relative
levels of TKP enzymes transcripts in sorted islets β-cells (open bars) and non β-cells
(hatched bars) are shown. Data are expressed as means ± SEM of four independent
experiments and quantiﬁed using 2−ΔCT method in log scale. * p b 0.05 as compared to
rat β-cell group.
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with 0.5, 5 and 10 mM glucose.
Rat islets (batch of 6 islets) were preincubated in KRBH—0.2% BSA
with 2.8 mM glucose for 1 h, followed by 90 min incubation in
KRBH—0.2% BSA with 2.8 or 16.7 mM glucose to measure glucose-
induced insulin secretion.
In some protocols, rat islet insulin release was measured during a
perifusion procedure as previously described [38]. Eight freshly isolated
islets at a time were allowed to attach on a polylysine-treated cover-
glass transferred to a perifusion chamber placed on the stage of an
inverted microscope (Diaphot, Nikon, France). Cannulas feeding into
the chamber were connected to a peristaltic pump and allowed a
continuous perifusion of the islets at a ﬂow rate of 1 ml/min with a
25 mM Hepes-buffered medium maintained at 37 °C, containing (in
mM) 125 NaCl, 5.9 KCl, 1.28 CaCl2, 1.2 MgCl2, and 2.8 or 16.7 glucose
(G2.8, G11), and 1 mg/ml BSA. The perifusion ﬂuid was collected from
the chamber at 60 s intervals and stored at−20 °C for insulin radioim-
munoassay. The insulin concentration in the medium was determined
by ELISA (Alpco) [41].
2.11. Statistical analysis
Results are expressed as means ± S.E.M. Signiﬁcance was assessed
using Student's unpaired and two-tailed t tests. P N 0.05 was considered
signiﬁcant.
3. Results
3.1. Detection of transcripts encoding TKP enzymes
In freshly isolated normal rat islets, all the TKP transcripts (TDO2,
KMO, Kase, KAT1, KAT2, KAT3, KAT4, QPRT, NAMPT) were detected,
except those of IDO1 and ACMSD. The levels of expression varied
considerably across the different genes, with transcripts encoding
KAT4 detected at the highest level (Fig. 2A).
Interestingly, after 48 h in culture, the hierarchy in the expression
proﬁle of the TKP genes was maintained (data not shown).
The INS-1 cells also exhibited differentially expressed TKP genes
(Fig. 2B) and at variance with the primary rat islet cells, KMO and
Kase transcripts remained undetected. Since it has been reported by
others [31,42] that if one TKP enzyme is different, the production of
the downstream KP metabolites can be totally different, one may
conclude that INS-1 cells cannot be used as a blue-print of primary rat
β-cells to investigate the TKP.
In separate experiments we also measured the TKP transcripts
separately in β-cells and non β-cells isolated from normal rat islets
maintained in a standard culture medium for 48 h (Fig. 2C). In the β-
cell rich fraction (88% purity) of cells issued from islets, the levels of
transcripts encoding IDO1 were undetectable, as they were in the non
β-cell fraction (Fig. 2C). Transcripts encoding TDO2, KMO or KAT3
were similarly expressed in both cell populations (Fig. 2C), while
those of Kase (0.46 fold, p b 0.05), KAT1 (1.7, fold), KAT2 (1.4 fold,
p b 0.05), KAT4 (1.8 fold, p b 0.05), NAMPT (1.5 fold, p b 0.05) and
QPRT (8.6 fold, p b 0.05) in the non β-cell population were signiﬁcantly
different compared to β-cell population. ACMSD transcripts were
undetectable in β-cells as well as non β-cells.
3.2. Modulation of TKP transcript levels by proinﬂammatory cytokines
The potential effects of IFN-γ on TKP transcriptswere investigated in
cultured rat islets and INS-1 cells after a 48 h-exposure (Fig. 3).
In the INS-1 cells exposed to IFN-γ, the effect on IDO1mRNAwas the
most remarkable (50 fold; p b 0.05) (Fig. 3A). KMO and Kase transcripts
remained undetectable. QPRT, NAMPT and KAT3 were signiﬁcantly up
regulated (by 1.6, 1.6 and 1.7 fold; p b 0.01, p b 0.01 and p b 0.05 respec-
tively). In the INS-1 cells exposed to IFN-γ, the TKP transcript changeswere observed in the presence of both increased cell apoptosis as
estimated by increased caspase 3 activity (6.5 fold; p b 0.01) (Fig. 3D),
and of impaired insulin release as estimated by decreased glucose-
induced insulin secretion (Fig. 3E).
Also in rat islets treated with IFN-γ (2500 U/ml), the levels of
transcripts encoding IDO1 were signiﬁcantly increased (N140-fold
compare to detection threshold; p b 0.05) compared to untreated
cultures, which were inferior to detection threshold (Fig. 3B).
Transcripts encoding TDO2, on the other hand, were slightly but not
signiﬁcantly down-regulated in IFN-γ treated islets as compared to
controls (Fig. 3B). Transcripts encoding KMO, KAT1, KAT2, KAT4, Kase
or QPRT were not signiﬁcantly affected by the cytokine treatment
(Fig. 3B),while those of KAT3 andNAMPTwere signiﬁcantly up regulat-
ed (by 1.7 and 1.6 fold; p b 0.01 and p b 0.05 respectively). These TKP
transcript changes in the rat islets exposed to IFN-γ, were not correlated
to impaired insulin release since glucose-induced insulin secretion
remained normal (Fig. 3F).
Fig. 3.Modulation of TKP transcript levels, insulin-cell survival and insulin secretion by proinﬂammatory cytokines. Changes in levels of transcripts encoding TKP enzymes in INS-1 cells
challenged with IFN-γ (2500 U/ml) (A), rat islets challenged for 48 h with IFN-γ (2500 U/ml) (B) or IL-1β (100 U/ml) (C). Caspase 3 activity (D) and glucose-induced insulin secretion
(E) by INS-1 cells challenged with IFN-γ (2500 U/ml). Glucose-induced insulin secretion by rat islets challenged with IFN-γ (2500 U/ml) for 48 hrs (F) or challenged with IL-1β
(100 U/ml) for 48 h (G). Data are expressed as means ± SEM of four independent experiments. * p b 0.05, ** p b 0.01 as compared to related untreated control group (A,B,C,D) or to
untreated islets at 2.8 mM glucose (G).
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48 h-exposure. As indicated in Fig. 3C, 500U/ml IL-1β induced a robust
expression of IDO1 (26 fold compared to detection threshold;
p b 0.01), of KMO (19 fold; p b 0.01) and exerted some upregulating
effect on Kase (1.8 fold; ns), NAMPT (2.3 fold, p b 0.01) and QPRT (1.8
fold; ns) expression. IL-1β also inhibited the expression of TDO2
(0.24fold; p b 0.05), KAT1 (0.49 fold; p b 0.01) and KAT3 (0.58 fold;
p b 0.05). These TKP transcript changes in the rat islets exposed to IL-
1β, were observed in the presence of impaired insulin release as
estimated by decreased glucose-induced insulin secretion (Fig. 3G).
3.3. Modulation of TKP transcript levels by glucolipotoxicity
The potential effects of a 48 h-exposure to the combination high
glucose (HG, 20 mM glucose)/high fat (HF, 0.4 mM palmitate) on TKP
transcripts were investigated in INS-1 cells and cultured rat islets
(Fig. 4).
In the INS-1 cells exposed to HGHF, IDO1, Kase transcripts and KMO
transcripts remained undetectable. Transcripts encoding KAT2, KAT4,
QPRT and NAMPT were not signiﬁcantly affected by HGHF treatment
(Fig. 4A), while those of KAT1 and KAT3 were decreased (by 0.6 and
0.1 fold; p b 0.01).
In INS-1 cells exposed to HGHF, the TKP transcript changes were
observed in the presence of both increased cell apoptosis as estimated
by increased caspase 3 activity (N2.4 fold; p b 0.05) (Fig. 4C), and ofimpaired insulin release as estimated by decreased glucose-induced
insulin secretion (0.28 fold; p b 0.01 at G10) (Fig. 4D).
The TKP transcript pattern in rat islets treated with HGHF was
different: the level of TDO2 transcripts was slightly but not signiﬁcantly
down-regulated; that of IDO1 transcripts remained undetected, and
that of KMO transcripts was signiﬁcantly increased (7.6 fold; p b 0.05)
as compared to values in untreated cultured islets (Fig. 4B). Transcripts
encoding KAT4, QPRT and NAMPT were modestly but signiﬁcantly
increased (by 1.5, 2.2 and 2.4 fold respectively; p b 0.01, p b 0.05 and
p b 0.05 respectively) by HGHF treatment (Fig. 4B), while those of
KAT1, KAT2 and KAT3 were modestly decreased (by 0.52, 0.5 and 0.51
fold respectively; p b 0.01 p b 0.05 and p b 0.01 respectively). These
TKP transcript changes in the rat islets exposed to HGHFwere observed
in the presence of impaired insulin release as estimated by decreased
glucose-induced insulin secretion (Fig. 4E).
3.4. Modulation of TKP transcript levels by oxidative stress
The potential effects of exposure to a calibrated oxidative stress
(50 μMH2O2) on TKP transcripts were investigated in cultured rat islets
and INS-1 cells (Fig. 5).
In the INS-1 cells exposed to H2O2, IDO1, KMO, Kase and ACMSD
transcripts remained undetectable (Fig. 5A). Transcripts encoding
TDO2, QPRT,NAMPT, KAT1, KAT2, KAT3 andKAT4were not signiﬁcantly
changed (Fig. 5A). In the INS-1 cells exposed to H2O2, the TKP transcript
Fig. 4.Modulation of TKP transcript levels, insulin-cell survival and insulin secretion by glucolipotoxic environment. Changes in levels of transcripts encoding TKP enzymes in INS-1 cells
(A) or rat islets (B) challenged with glucolipotoxic medium (HGHF) (20 m M glucose and 0.4 m M palmitate) during 48 h. Caspase 3 activity (C) and glucose-induced insulin secretion
(D) by INS-1 cells challenged with HGHF. Glucose-induced insulin secretion by rat islets challenged with HGHF for 48 h (E). Data are expressed as means ± SEM of four independent
experiments. * p b 0.05, ** p b 0.01 as compared to related untreated control group (A,B,C,D), to untreated INS1 cells at 0.5 mM glucose (D) or to untreated islets at 2.8 mM glucose (E).
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fold; p b 0.01) (Fig. 5C), while the glucose-stimulated insulin release
capacity remained unaffected (Fig. 5D).
In rat islets treated with H2O2, none of the TKP transcript levels was
increased. Rather, they were globally down-regulated as compared to
control levels (Fig. 5B), either non signiﬁcantly (TDO2, KMO, Kase,
QPRT) or signiﬁcantly (KAT1, KAT3, KAT4: by 0.5, 0.77 and 0.7 fold
respectively; p b 0.01). Transcripts encoding IDO1 remained undetect-
able. NAMPT and KAT2 transcript levels were not affected.Fig. 5.Modulation of TKP transcript levels, insulin-cell survival and insulin secretion by oxidative
(B) challengedwith oxidativemedium (50 μMH2O2) for 30min, thenwashed and cultured for 4
INS-1 cells challenged with oxidative medium (50 μMH2O2) for 30min, then washed and cultu
experiments. * p b 0.05, ** p b 0.01 as compared to related untreated control group (A,B,C).3.5. Modulation of TKP transcript levels by glucocorticoids
The potential effect of corticosterone on TKP transcripts was investi-
gated in cultured rat islets after a 48 h-exposure (Fig. 6).
In rat islets treated with corticosterone (10 μM) the levels of
transcripts encoding IDO1 were slightly induced (N1.8 fold compared
to detection threshold; p = 0.3) (Fig. 6A) compared to untreated
cultures which were inferior to detection threshold. Transcripts
encoding TDO2, on the other hand, were slightly down-regulatedstress. Changes in levels of transcripts encoding TKP enzymes in INS-1 cells (A) or rat islets
8 h in normalmedium. Caspase 3 activity (C) and glucose-induced insulin secretion (D) by
red for 48 h in normal medium. Data are expressed as means ± SEM of four independent
Fig. 6.Modulation of TKP transcript levels, insulin-cell survival and insulin secretion by glucocorticoid. Changes in levels of transcripts encoding TKP enzymes (A) and glucose-induced
insulin secretion (B) in rat islets challengedwith corticosterone (10 μM) for 48 h. Data are expressed asmeans± SEM of four independent experiments. ** p b 0.01 as compared to related
untreated control group (A) or to untreated islets at 2.8 mM glucose (B).
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controls (Fig. 6A). Transcripts encoding KMO, Kase, QPRT, NAMTP,
KAT1, KAT3 and KAT4 were not signiﬁcantly affected by corticosterone
treatment (Fig. 6A),while those of KAT2were signiﬁcantly up regulated
(by 6.9 fold; p b 0.01). ACMSD transcripts were undetectable. These TKP
transcript changes in the rat islets exposed to corticosterone, were
observed in the presence of impaired insulin release as estimated by
decreased glucose-induced insulin secretion (Fig. 6B).3.6. Modulation of TKP transcript levels by the combination
cytokines + glucolipotoxicity
In additional experiments we measured the TKP transcripts
separately in β-cells and non β-cells isolated from normal rat isletsA
Fig. 7. TKP transcript levels in isolated rat β-cells and nonβ-cells exposed to the combination g
isolated rat islets were cultured in a combination of glucolipotoxic medium (HGHF) and IFN-γ
sorted by FACS into a β-cell fraction (open bars) and a non β-cell fraction (hatched bars). Cha
(A). IDO1 immunodetection was performed in β-cell fractions obtained without (B) or after ex
four independent experiments. * p b 0.05, ** p b 0.01 as compared to related untreated controlpreviously exposed during 48 h to the combination IFN-γ + HGHF
(Fig. 7A).
In the β-cell rich fraction of cells issued from islets treated with the
combination, the levels of transcripts encoding IDO1 were strongly
and signiﬁcantly induced (570 fold compared to detection threshold;
p b 0.05) compared to untreated control β-cells (Fig. 7A). KMO
transcripts were also signiﬁcantly increased (N8 fold; p b 0.05) as
compared to values in untreated β-cells (Fig. 7A). Transcripts encoding
TDO2, Kase, KAT1, KAT2 or QPRT were not signiﬁcantly affected
(Fig. 7A), while those of NAMPT, KAT3 and KAT4 were modestly but
signiﬁcantly upregulated (by 2, 1.9 and 1.6 fold respectively; p b 0.01
p b 0.05 and p b 0.01 respectively).
In the non β-cell rich fraction of cells issued from islets treated with
the combination, the pattern was not identical. While the levels of
transcripts encoding IDO1were also strongly and signiﬁcantly increasedlucolipotoxic medium+ IFN-γ, and IDO1 immunodetection in isolated rat β-cells. Freshly
(20 mM glucose, 0.4 mM palmitate and 2500 U/ml IFN-γ) for 48 h, then trypsinized and
nges in levels of transcripts encoding TKP enzymes were quantiﬁed in both populations
posure of rat islets to IFN-γ treatment (C). Data in (A) are expressed as means ± SEM of
group.
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KMO transcripts were not signiﬁcantlymodiﬁed (0.98 fold; p=0.96) as
compared to values in untreated non β-cells (Fig. 7A). Kase transcripts
were slightly upregulated, but the difference as compared to control
did not reach statistical signiﬁcance (3.6 fold; p = 0.055). Transcripts
encoding TDO2, KAT1, KAT2, and KAT4 were not signiﬁcantly affected
(Fig. 7A), while those of NAMPT and KAT3 were up-regulated (by 1.4
and 3 fold respectively; p b 0.05 and p b 0.01 respectively) and those
of QPRT were down-regulated (by 0.18 fold; p b 0.05) (Fig. 7A).
ACMSD transcripts were undetectable in both cell fractions (Fig. 7A).
3.7. IDO1 and KMO protein expression and localization in normal rat
pancreas and islet cells
We were also unable to detect any IDO1 immunoreactivity in
endocrine cells as well as while exocrine tissue in the basal normal
situation (data not shown). In additional experiments, we analyzed
IDO1 immunolocalization separately in β-cells isolated from normal
rat islets previously exposed in vitro during 48 h to IFN-γ. Under these
conditions only, all the β-cells exhibited a discrete IDO1 co-labeling
(Fig. 7C).
Western blot analysis detected basal expression of KMO protein in
rat islets cultured 48 h in normal medium (Fig. 8I) and showed signiﬁ-
cant increase of KMO protein in response to IL-1β (Fig. 8I). Immunoﬂu-
orescence analysis performed on whole adult rat pancreatic sections
demonstrated the presence of a strong KMO immunoreactivity in
glucagon positive cell and a very faint immunoreactivity in insulinFig. 8. KMO protein expression and immunolocalization. KMO immunolocalization was perform
(B) and 13 day old rat fetuses (C). 2/ in rat islets after 48 h culture in normal medium (D), HGH
(20 mM glucose, 0.4 mM palmitate and 2500 U/ml IFN-γ) (F); 3/ in isolated rat β-cells sorted f
(20 mM glucose, 0.4 mMpalmitate and 2500 U/ml IFN-γ) (H). Western blot analysis for KMO p
1) or in medium containing 500 U/ml IL-1β (lane 2). Data in (I) are expressed as means ± SEMpositive cells, while exocrine tissue was devoided of any staining
(Fig. 8A). Fig. 8 also provides images of KMO staining at different ages
(pancreas at neonatal age day 7; pancreatic bud at embryonic age day
13) (Figs. 8B and 8C respectively) and co-localization with glucagon
(Figs. 8B and C). From these example images, it is clear that the highest
intensity of KMO immunostaining under basal state, whatever the age,
co-localizes with glucagon and thus occurred within the α-cells.
In the islets cultured 48 h in normal medium, KMO expression was
maintained and KMO staining was mostly located in the α-cells, since
it co-localized with glucagon rather than insulin (Fig. 8D). In the islets
exposed to HGHF conditions, KMO immunoreactivity became strongly
increased in the insulin positive cells (Fig. 8E).
In additional experiments we also analyzed KMO immunolocaliza-
tion separately in β-cells and non β-cells isolated from normal rat islets
previously exposed during 48 h to normal culture medium (Fig. 8G) or
the combination IFN-γ+HGHF (Fig. 8H). Immunoﬂuorescence analysis
performed on β-cells and non β-cells puriﬁed from untreated cultured
islets, showed that all the insulin-positive cells were negative for KMO
immunoreactivity and the KMO-positive cells were insulin-negative
(Fig. 8G) and glucagon-positive (data not shown). A strong increase in
the number of KMO immunopositive cells was observed in response
to IFN-γ+ HGHF, that included both insulin immunoreactive β-cells
((Fig. 8H) and non β-cells (data not shown). However, KMO staining
was the strongest in the insulin-negative cells (non β-cells) and milder
in the insulin-positive cells (β-cells). In this respect, the response in
puriﬁed islet cells paralleled the effects detected by immunoﬂuores-
cence analysis in intact islets.ed: 1/ in total pancreatic tissue from 12week old normal rats (A), 7 day old newborn rats
F medium (20mM glucose and 0.4 mM palmitate) (E), or the combination HGHF+ IFN-γ
rom rat islets cultured for 48 h in normal medium (G), or the combination HGHF + IFN-γ
rotein expression (I) was performed in rat islets cultured for 48 h in normal medium (lane
of four independent experiments. * p b 0.05 as compared to control group.
Fig. 9. KYN and KYNA production by normal rat islets exposed to various treatments in vitro. Groups of 200 normal rat islets were cultured for 48 h in medium under the indicated
conditions. KYN (A) and KYNA (B) accumulations in the medium supernatants were measured by LC-MS/MS. Results were normalized to islet total protein content. In each condition,
the KYN over KYNA ratio was calculated (C). Data are expressed as means ± SEM of four independent experiments. * p b 0.05 as compared to control group.
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To address potential functionality of the TKP in the cultured islets,
we quantiﬁed the accumulation of KYN and KYNA in the islet culture
media at the end of the 48 h culture period, after exposure to the various
treatments (Fig. 9). First, levels of KYN and KYNA were detectable in
medium from untreated cultured islets (Fig. 9). Notably, KYNA release
represented only 10% of KYN release under this basal situation. Second,
signiﬁcantly (p b 0.05) higher levels were detected in media of islets
treated with IFN-γ (by 1.4 fold) and the combination IFN-γ+ HGHF
(by 1.4 fold). HGHF or IL-1β had only a slight increasing effect which
remained not statistically signiﬁcant. Corticosterone did not affect KYN
release (Fig. 9A). Concerning islet KYNA release, it was only signiﬁcantly
affected in response to corticosterone exposure (decreased by 0.7 fold;
p b 0.05) (Fig. 9B). When islet KYN release was expressed as a function
of islet KYNA release, it appeared to be clearly increased (p b 0.01) in
response to IFN-γ, HGHF, IFN-γ+ HGHF and corticosterone (Fig. 9C),
but not to IL-1β.3.9. Extracellular Trp, KYN and KYNA modulate GSIS by normal rat islets
Since we have shown that normal W rat islets spontaneous release
signiﬁcant levels of the TKP metabolites KYN and KYNA, it is reasonable
to ask the question whether or not Trp, KYN and KYNA are able to
modulate islet GSIS. To that aim, freshly isolated normal rat islets were
perifused in the presence or absence of the metabolites. The kinetic of
insulin release in the perifusion buffer is illustrated by Fig. 10. Cumula-
tive values of insulin secretion during the glucose stimulation period
(area under curve) are shown in the inset of Fig. 10. During perifusion
with a submaximal stimulatory glucose concentration (11 mM),
addition of 0.1 mM KYN signiﬁcantly ampliﬁed the insulin release (2.2
fold, p b 0.01 compared to control group) (Fig. 10). 0.1 mM Trp or
KYNA also ampliﬁed the GSIS by normal islets, but more modestly and
the differences did not reach statistical signiﬁcance (Fig. 10).Fig. 10. Kinetics of glucose-induced insulin secretion by normal rat islets in response to
Trp, KYN or KYNA. Groups of 30 normal rat islets were perifused with Hepes buffer
containing 2.8 mM glucose (G2.8) or 11 mM glucose ± 100 μMmetabolites as indicated.
The secretion of insulin was normalized by the basal secretion at 2.8 mM glucose.
Cumulative secretion values (AUC) during the stimulation period (22–40 min) are
indicated in the inset graph. Data are means ± SEM of 7 experiments in each group.
** p b 0.01 compared with the control group (C).4. Discussion
We here report, for the ﬁrst time, that rat pancreatic islet cells and
the rat INS-1β-cell line express detectable levels of transcripts encoding
the different enzymes of the TKP. Importantly, this is associatedwith the
spontaneous release of signiﬁcant levels of the TKPmetabolites KYNand
KYNAby the rat islets, therefore suggesting somedegree of functionality
of the TKP in the rat islet cells in the basal situation. Substantial
differences in the basal levels of expression across genes were also
maintained during culture and likely reﬂect a stable and genuine
genomic pattern.Our results ﬁrst show that IDO1 transcript and IDO1 protein are not
expressed in the rat pancreatic islet under basal unstimulated condition,
similarly to the human islet [36]. We demonstrated that IFN-γ alone or
IL-1β strongly activate IDO1 mRNA accumulation in rat islets. By
contrast, exposure to HGHF or H2O2 did not activate IDO expression,
at least under our experimental setting which was nevertheless
sufﬁcient to deteriorate INS-1 cell survival and glucose-stimulated
insulin secretion. Also in human islets, an effect of IFN-γ on IDO1 tran-
scripts has been documented in microarray proﬁling experiments [36,
43]. Concerning IDO1 protein expression, our FACS-puriﬁed cell experi-
ments suggest that IFN-γ activates accumulation of IDO protein in both
rat β-cells and non β-cells, but the speciﬁc immunostaining signal
remained faint. More convincing to support the involvement of IDO1
activation following treatment with IFN-γ, is our ﬁnding that IFN-γ
increased KYN release by the rat islets while KYNA release remained
unchanged. Increased levels of TKP metabolites and increased levels of
transcripts encoding IDO1 have been also reported following IFN-γ
treatment of human fetal astrocytes [14], human skin ﬁbroblast cultures
[44] and in primary neurons and neuroblastoma cells [13]. Concerning
IL-1β, a recent report demonstrated that it induced an up-regulation
of IDO1 transcripts in human hippocampal progenitor cells [45], an
observation consistent with our ﬁnding. In addition, our results show
a faint IDO1 induction by corticosterone, as we detected a very tiny
amount IDO1 amplicon in the corticosterone-treated samples compared
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ity, the result did not reach statistical signiﬁcance.
TDO2 transcripts and protein were moderately expressed in the rat
pancreatic islet under basal unstimulated condition (as well as in
the INS-1 cell line). IFN-γ, IL-1β, HGHF, or the combination IFN-
γ+ HGHF, induced a decrease of the level of TDO mRNA in rat islets,
which became signiﬁcant in response to IL-1β. Also in neuroblastoma
cells, levels of transcripts encoding TDO2 were reduced by IFN-γ [13]
and a switch between IDO1/TDO2 after IFN-γ stimulation has been
previously described in humanneurons [31]. Exposure to corticosterone
did not activate islet TDO2 expression (either transcripts or protein), at
variance with the effect reported in liver. Unfortunately, lack of a
suitable antibody did not allow immunohistochemical studies of TDO2
protein.
In the KYNA branch of the TKP, four subtypes of KAT have been
identiﬁed within the brain, with KAT2 being the most abundant in rat
and human brain [46]. The four KAT enzymes were found constitutively
expressed in rat pancreatic islets as well as in the INS-1 cells, with KAT
transcripts detected at the highest level compared to the other TKP
transcripts. Except a faint increase of KAT3 transcript, we observed no
effect, or only marginally either increased or decreased levels of
transcripts encoding the other KAT enzymes in response to IFN-γ expo-
sure. Our observations are in line with the effects of IFN-γ observed in
human ﬁbroblasts [44] or neuronal cells [13], as there is no consensus
in earlier studies regarding the response of the KAT enzymes to IFN-γ
treatment. Whereas increases in the levels of KAT 1 and KAT 2 were
observed in fetal astrocytes following IFN-γ treatment [14], no effect
on the levels of transcripts encoding these enzymes was observed in
neuronal cells [13]. In neuroblastoma cells, the IFN-γ treatment did
not modify the levels of transcripts encoding KAT1 and KAT2 [13].
In the NAD branch of the TKP, KYN serves as a substrate for KMO,
resulting in the production of 3-hydroxykynurenine (3HK) which is
further degraded to 3-hydroxyanthranilic acid (3HAA) through the
action of Kase. We found that rat pancreatic islets (but not INS-1 cells)
constitutively express KMO under basal unstimulated condition. 48 h-
exposure of rat islets to HGHF induced an upregulation of transcripts
for KMO (7.6 fold; p b 0.05). IL-1β also upregulated the KMO transcripts
(19 fold; p b 0.01) andKMOprotein (2.5 fold; p b 0.05). By contrast, IFN-
γ exposure (or H2O2) did not signiﬁcantly affect KMOmRNA, under our
experimental setting, and it did not potentiate the HGHF-induced KMO
expression. Our immunohistochemical data suggest that HGHF
activates accumulation of KMO protein mostly in rat β-cells as shown
by our FACS-puriﬁed cell experiments. This is in accordance with the
data related to KMO mRNA accumulation in basal or IFN-γ + HGHF
conditions, in the β-cell fraction. In human skin ﬁbroblast cultures, a
lack of effect on transcripts encoding KMO following IFN-γ treatment
[40] was also reported, while Heyes et al. [47] mentioned a small
increase in KMO activity in IFN-γ exposed monocytes. Concerning IL-
1β, it induced anup-regulation of KMO transcripts in humanhippocam-
pal progenitor cells [45].
Rat pancreatic islets (but not INS-1 cells) constitutively express Kase
under basal unstimulated condition. FACS-puriﬁed cell experiments in-
dicated that Kase transcripts were present in β-cells as in non β- islet
cells. Levels of transcripts encoding Kase enzyme were not signiﬁcantly
modiﬁed in response to IFN-γ, IL-1β, HGHF, H2O2 or the combination
HG/HF + IFN-γ.
A similar pattern of expression was observed for QPRT, with detect-
able QPRT transcripts in β-cells as in non β-cells in basal condition, no
signiﬁcant alteration in response to IFN-γ, IL-1β, H2O2 or the combina-
tion HGHF+ IFN-γ, and amoderate but signiﬁcant increase in response
to HGHF.
Rat pancreatic islets and INS-1 cells did not express ACMSD either in
basal unstimulated condition or in response to IFN-γ, IL-1β, HGHF,
H2O2, or the combination HGHF + IFN-γ.
Rat pancreatic islets as well as INS-1 cells constitutively express
NAMPT under basal unstimulated condition. FACS-puriﬁed cellexperiments indicated that NAMPT transcripts were present in β-cells
as in non β-cells. Levels of transcripts encoding NAMPT enzyme were
upregulated in response to IFN-γ (1.6 fold p b 0.01), HGHF (2.4 fold;
p b 0.05), IL-1β (2.3 fold; p b 0.01), while they remained unchanged
after H2O2. At variancewith lack of data related to expression and effect
of TKP enzymes upstreamNAMPT in islet cells, there are several reports
indicating that NAMPT expression is detected in human islets (both in
β- and non β-cells) and increased by high glucose [48,49]. This is in
line with our present ﬁndings in rat islets. NAMPT is a rate-limiting
enzyme in the mammalian NAD+ salvage and it exists in two known
forms, intracellular NAMPT (iNAMPT) and a secreted form, extracellular
NAMPT (e NAMPT). eNAMPT is also known as both pre-B cell colony
enhancing factor (PBEF) due to its function as a cytokine, and visfatin
due to its role as an adipokine. Itmay also act as an extracellular enzyme
converting extracellular nicotinamide to nicotinamide mononucleotide
(NMN). NMN is an intermediate product in NAD+ salvage pathway,
may be taken up by cells and is utilized to generate NAD+/NADH.
Finally, to summarize our present ﬁndings, despite the lack of IDO1,
the normal rat islet constitutively expresses transcripts encoding the
different enzymes of the KYNA branch of the TKP (KATs). It also express
enzymes of the QUIN/NAD branch (KMO, Kase, QPRT), while the lack of
ACMSD expression makes PIC or glutaryl-CoA production unfeasible.
Our data also show that islet IDO1 and KMO are main targets regulated
by environmental conditions associated to obesity/diabetes, since IDO1
expression is activated by cytokines (but not by HGHF or oxidative
stress) while KMO expression is prominently activated by HGHF and
IL-1β (but not or to lesser extent, by IFN-γ, oxidative stress or glucocor-
ticoid). The many discrepancies identiﬁed here between islet cells and
other cell types in response to cytokines or HGHF, reﬂect probably
intrinsic differences across cell types in transcription of genes encoding
TKP enzymes and in their abilities to form active TKP metabolites such
as KYN, KYNA or QUIN [47]. The enzymes participating in the TKP,
when expressed, are distributed at similar levels in both rat β-islet
cells and non β-islet cells, except α-cells which harbor more KMO and
QPRT. Also in the central nervous system, the TKP enzymes are found
differently distributed among the different cells: the microglial cells
harbor little KAT, and the astrocytes contain hardly any KMO with
KYNA production therefore attributed mainly to astrocytes, while
microglial cells are primarily responsible for the synthesis of QUIN [30].
The physiological role of the TKP in pancreatic islets is not known.
Since the ﬁrst description of the TKP in CNS thirty-some years ago,
this pathway stays inclined towards unique properties as an interface
between the immune systemand neuronal signaling, since it is sensitive
to inﬂammatory signaling and its products have neuromodulatory
properties. Moreover, recent studies in yeast, worm, ﬂies and mice
have now established that TKP metabolism can also function as a
regulator in lifespan and cancer [37]. In addition to its participation in
NAD+ homeostasis, the TKP generates a number of biologically active
intermediate metabolites. QUIN is an excitatory (excitotoxic) agent at
NMDA-type glutamate receptors and synergizes with 3-HK to produce
oxidative stress. KYNA is an inhibitor of glutamate neurotransmission
and possibly an antagonist at nicotinic α7 receptors. In addition to
NMDA, AMPA and nicotinic α7 receptors, KYNA is reported to interact
with GPR35 [50] and aryl hydrocarbon receptors [50].
Support for a tolerogenic role for TKP activation in islets in vivo has
come from the observation that adenovirus-mediated IDO expression
in transplanted NOD islets prolonged their survival in NOD/SCID recip-
ients that received diabetogenic splenocytes [51,52]. These effects
were in part attributed to local depletion and perturbation of the func-
tion of activated B and T lymphocytes by local depletion of free Trp
[51,52]. Although Trp depletion is the favored mechanistic explanation
for the tolerogenic effect of IDO1 activation, KYN and PIC can directly
inhibit T-cell proliferation [51,52]. The release of Trp metabolites such
as 3-HK, 3-HAA, QUIN and PIC could also provide bystander inhibition
of immune cell function. Concerning the potential effects of the
TKP on the insulin secretion, information are very scarce and poorly
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acutely block leucine-stimulated insulin secretion by rat islets [53],
and to the best of our knowledge, no study related to effect of TKP
metabolites onGSIS (which is the best reﬂection of the functional health
of the beta-cell).Therefore our report that KYN signiﬁcantly ampliﬁed
GSIS by normal rat islets is the ﬁrst one. Of course, it remains in the
near future to identify themechanisms bywhich KYN or KYNA potenti-
ate GSIS. This will not be an easy task since sources of KYN or KYNAmay
act intracellular as well as extracellular, separately or additively, to
modulate GSIS. The acute effect of KYN is possibly related to its ability
(or its metabolites) to interact with some speciﬁc receptors. Our future
studies should include the expression of receptors for KYN and its
metabolites, such as AHR, GPR35, NMDA and AMPA proteins in normal
rat islets.
In conclusion, we have demonstrated for the ﬁrst time in normal rat
pancreatic islets, that: 1/only some TKP genes are constitutively
expressed, both in β-cells as well as non β-cells; 2/ the regulatory
enzyme indoleamine 2,3-dioxygenase (IDO1) is not constitutively
expressed; 3/ IDO1 and kynurenine 3-monoxygenase (KMO) expres-
sion is potently activated by proinﬂammatory cytokines (IFN-γ, IL-1β)
and glucolipotoxicity respectively, rather in β-cells than in non β-
cells; 4/ islet kynurenine/kynurenic acid production ratio is enhanced
following IFN-γ and glucolipotoxicity; 5/ acute exposure to KYN
potentiates glucose-induced insulin secretion by normal islets; and 6/
oxidative stress or glucocorticoidmodulates TKP genes only marginally.
Therefore the pancreatic islets may represent a new target tissue for
inﬂammation and glucolipotoxicity to activate the TKP pathway. Of
course the next step will be to evaluate the functional impact the
various TKP metabolites have upon the islet cells. Most importantly,
since inﬂammation is now recognized as a crucial mechanism in the
development of the metabolic syndrome [46] and more speciﬁcally at
the islet level [34], it is therefore needed to evaluate the potential induc-
tion of the TKP in the endocrine pancreas during obesity and/or diabetes
and its relationship to the islet cell functional alterations.Authors' contributions
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